Researchmoz Global Pvt. Ltd.

ResearchMoz : Respiratory Syncytial Virus (RSV) Infections Global Clinical Trials Review Report Share 2014

Most up-to-date research on "Respiratory Syncytial Virus (RSV) Infections Global Clinical Trials Review, H2, 2014" to its huge collection of research reports.

 

Albany, NY -- (SBWIRE) -- 12/23/2014 -- Summary

GlobalData's clinical trial report, Respiratory Syncytial Virus (RSV) Infections Global Clinical Trials Review, H2, 2014" provides data on the Respiratory Syncytial Virus (RSV) Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Respiratory Syncytial Virus (RSV) Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Respiratory Syncytial Virus (RSV) Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Browse Detail Report With TOC
http://www.researchmoz.us/respiratory-syncytial-virus-rsv-infections-global-clinical-trials-review-h2-2014-report.html

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

- Listings of discontinued trials (suspended, withdrawn and terminated)

For Market Research Latest Reports Visit
http://www.researchmoz.us/latest-report.html

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner

- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

- Obtain discontinued trial listing for trials across the globe

- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Related Reports

Respiratory Syncytial Virus (RSV) Infections Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

(http://www.researchmoz.us/respiratory-syncytial-virus-rsv-infections-market-analysis-global-api-manufacturers-and-phase-iii-pipeline-assessment-2014-report.html)
DelveInsights, Respiratory Syncytial Virus (RSV) Infections- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions.

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022

(http://www.researchmoz.us/pharmapoint-pediatric-respiratory-syncytial-virus-rsv-prophylactics-us-drug-forecast-and-market-analysis-to-2022-report.html)

Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected persons sneeze or cough, or through direct and indirect contact with nasal secretions of an infected person. The majority of RSV infections present as mild upper respiratory illnesses that often self-resolve within two weeks, but about 1% of the cases develop serious lower respiratory complications requiring hospitalization. Children under the age of two with certain health conditions are most at risk for severe RSV infections and are therefore recommended to receive RSV prophylaxis treatments. The only FDA-approved prophylactic intervention in the US is AstraZenecas Synagis (palivizumab), a humanized monoclonal antibody against the fusion protein of the virus.

For More Reports Browse
https://www.linkedin.com/today/author/68229468

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
Email: sales@researchmoz.us